Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

"Dementia prevention" innovation to be trialled in US

03.12.2004


A vitamin B pill that drastically lowers blood levels of the toxic amino-acid homocysteine could one day be used to prevent dementia, and save health services billions of pounds annually.



Clinical trials, starting in January 2005, will seek to confirm that adding the B vitamins to a powerful antioxidant results in “prompt, striking and sustained clinical improvement” in patients. The move follows a licensing agreement this week between COBALZ Limited, a U.K. company specialising in homocysteine research, and Pamlab L.L.C, a U.S. company providing high-quality pharmaceuticals for general practices, neurology, cardiology and internal medicine.

It will enable a team led by Dr. Ramon Diaz-Arrastia of the University of Texas Southwestern Medical Center, to determine whether the antioxidant together with high-dose B vitamins is superior to standard B-vitamin supplements in slowing the rate of cognitive decline and the accumulation of MRI abnormalities in Alzheimer’s disease patients.


High blood levels of homocysteine are a risk factor for stroke and dementia, including Alzheimer’s disease. Raised levels damage nerves and blood vessels, and lead to a loss of brain tissue in patients. Although homocysteine can be lowered by standard B vitamin supplements it is not yet known whether these can be used to treat or prevent dementia. The few small studies to date are disappointing.

However, dementia is also associated with ‘free radicals’ which oxidise and damage an enzyme that breaks down homocysteine. COBALZ has found that adding a powerful antioxidant to B vitamins lowers homocysteine levels even further and results in prompt, striking and sustained clinical improvement in patients.

Neil McCaddon, Global Head of Licensing & Corporate Development for COBALZ, said: “We are very excited about the possibilities, and hope to announce some real breakthroughs for sufferers of dementia, and their carers.” Barry LeBlanc, President of Pamlab L.L.C., said: “Pamlab is very excited to incorporate COBALZ technology into its product line addressing hyperhomocysteinemia, and its role in mild cognitive impairment, vascular dementia and Alzheimer’s disease.”

Alzheimer’s disease is the leading cause of dementia in the elderly, afflicting an estimated 4.5 million people in the U.S. alone. COBALZ is now actively seeking other licensing and development partners for the rest of the global market.

Neil McCaddon | alfa
Further information:
http://www.cobalz.co.uk

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>